Last reviewed · How we verify

Traditional HBV Vaccine

NYU Langone Health · FDA-approved active Biologic

Traditional HBV Vaccine is a vaccine Biologic drug developed by NYU Langone Health. It is currently FDA-approved for Prevention of hepatitis B virus infection in unvaccinated or non-immune individuals, Post-exposure prophylaxis in non-immune individuals exposed to HBV.

The traditional HBV vaccine stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection.

The traditional HBV vaccine stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection. Used for Prevention of hepatitis B virus infection in unvaccinated or non-immune individuals, Post-exposure prophylaxis in non-immune individuals exposed to HBV.

At a glance

Generic nameTraditional HBV Vaccine
SponsorNYU Langone Health
Drug classvaccine
TargetHepatitis B surface antigen (HBsAg)
ModalityBiologic
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

The vaccine contains recombinant hepatitis B surface antigen (HBsAg) produced through recombinant DNA technology or purified from plasma. When administered, it triggers both humoral and cellular immune responses, leading to the production of anti-HBs antibodies and memory B cells. This immune response provides long-term protection against HBV infection by preventing viral attachment and entry into hepatocytes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Traditional HBV Vaccine

What is Traditional HBV Vaccine?

Traditional HBV Vaccine is a vaccine drug developed by NYU Langone Health, indicated for Prevention of hepatitis B virus infection in unvaccinated or non-immune individuals, Post-exposure prophylaxis in non-immune individuals exposed to HBV.

How does Traditional HBV Vaccine work?

The traditional HBV vaccine stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection.

What is Traditional HBV Vaccine used for?

Traditional HBV Vaccine is indicated for Prevention of hepatitis B virus infection in unvaccinated or non-immune individuals, Post-exposure prophylaxis in non-immune individuals exposed to HBV.

Who makes Traditional HBV Vaccine?

Traditional HBV Vaccine is developed and marketed by NYU Langone Health (see full NYU Langone Health pipeline at /company/nyu-langone-health).

What drug class is Traditional HBV Vaccine in?

Traditional HBV Vaccine belongs to the vaccine class. See all vaccine drugs at /class/vaccine.

What development phase is Traditional HBV Vaccine in?

Traditional HBV Vaccine is FDA-approved (marketed).

What are the side effects of Traditional HBV Vaccine?

Common side effects of Traditional HBV Vaccine include Injection site pain, redness, or swelling, Fever, Fatigue or malaise, Headache, Myalgia.

What does Traditional HBV Vaccine target?

Traditional HBV Vaccine targets Hepatitis B surface antigen (HBsAg) and is a vaccine.

Related